Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements

Journal of Hypertension

Volumn 21, Issue 7, 2003, Pages 1291-1298

  Smith, David H G ^a   Neutel, Joel M ^a   Lacourcière, Yves ^c   Kempthorne Rawson, Joan ^b  

^a Integrium   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c NONE

Author keywords

Ambulatory blood pressure monitoring; Angiotensin II receptor blocker; Blinded endpoint (PROBE) study; Double blind placebo controlled study; Hypertension; Meta analysis; Methodology; Open label; Prospective; Randomized

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; LOSARTAN; TELMISARTAN; VALSARTAN; ANTIHYPERTENSIVE AGENT; PLACEBO;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; COMPARATIVE STUDY; META ANALYSIS; METHODOLOGY; PROSPECTIVE STUDY; STATISTICS;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; DOUBLE-BLIND METHOD; HUMANS; HYPERTENSION; PLACEBOS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS;

EID: 0043095587     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200307000-00016     Document Type: Article

References (21)

1. ICH Steering Committee. Principles for clinical evaluation of new antihypertensive drugs. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceutical for Human Use. 2000.
2. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press 1992; 1:113-119.
3. Mancia G, Omboni S, Parati G, Ravogli A, Villani A, Zanchetti A. Lack of placebo effect on ambulatory blood pressure. Am J Hypertens 1995; 8:311-315.
4. Mallion JM, Siché JP, Lacourcière Y, the Telmisartan Blood Pressure Monitoring Group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13:657-664.
5. Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80 mg and valsartan 80 mg in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000; 16: 1123-1132.
6. Neutel JM, Kolloch RE, Plouin PF. Comparison of telmisartan monotherapy with losartan + HCTZ in mild-to-moderate hypertension [Abstract]. Am J Hypertens 2000; 13:58A-59A.
7. Fang J, Madhavan S, Cohen H, Alderman MH. Measures of blood pressure and myocardial infarction in treated hypertensive patients. J Hypertens 1995; 13:413-419.
8. Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JL, Ducimetiere P, et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30:1410-1415.
9. Millar JA, Lever AF, Burke V. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J Hypertens 1999; 17:1065-1072.
10. Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu L, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160:1085-1089.
11. Safar ME, Rudnichi A, Asmar R. Drug treatment of hypertension: the reduction of pulse pressure does not necessarily parallel that of systolic and diastolic blood pressure. J Hypertens 2000; 18:1159-1163.
12. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol 2000; 36:130-138.
13. Asmar R, Lacourcière Y. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. J Hypertens 2000; 18:1683-1690.
14. Domanski M, Norman J, Wolz M, Mitchell G, Pfeffer M. Cardiovascular risk assessment using pulse pressure in the first national health and nutrition examination survey (NHANES I). Hypertension 2001; 38: 793-797.
15. Lacourcière Y, Lenis J, Orchard R, Lewanczuk R, Houde M, Pesant Y, et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998; 3:295-302.
16. 1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens 1999; 17:293-302.
17. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15:206-217.
18. O'Brien E, Mee F, Atkins N, O'Malley K. Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society protocol. J Hypertens 1991; 9:573-574.
19. McGill JB, Reilly PA. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin Cardiol 2001; 24:66-72.
20. Muller JE. Circadian variation in cardiovascular events. Am J Hypertens 1999; 12:35S-42S.
21. Chasen C, Muller JE. Cardiovascular triggers and morning events. Blood Press Monit 1998; 3:35-42.